KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Notes Payables (2020 - 2024)

Historic Notes Payables for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Q1 2024 value amounting to $55000.0.

  • Recursion Pharmaceuticals' Notes Payables fell 9167.93% to $55000.0 in Q1 2024 from the same period last year, while for Mar 2024 it was $55000.0, marking a year-over-year decrease of 9167.93%. This contributed to the annual value of $41000.0 for FY2023, which is 5773.2% down from last year.
  • Recursion Pharmaceuticals' Notes Payables amounted to $55000.0 in Q1 2024, which was down 9167.93% from $41000.0 recorded in Q4 2023.
  • Recursion Pharmaceuticals' Notes Payables' 5-year high stood at $3.1 million during Q2 2021, with a 5-year trough of $41000.0 in Q4 2023.
  • Its 5-year average for Notes Payables is $645428.6, with a median of $96000.0 in 2022.
  • Its Notes Payables has fluctuated over the past 5 years, first plummeted by 9703.35% in 2022, then skyrocketed by 63157.89% in 2023.
  • Recursion Pharmaceuticals' Notes Payables (Quarter) stood at $1.1 million in 2020, then crashed by 91.61% to $90000.0 in 2021, then rose by 7.78% to $97000.0 in 2022, then crashed by 57.73% to $41000.0 in 2023, then soared by 34.15% to $55000.0 in 2024.
  • Its last three reported values are $55000.0 in Q1 2024, $41000.0 for Q4 2023, and $695000.0 during Q3 2023.